TH-302 has antileukemia activity in an in vivo primary AML xenograft murine model. TH-302 has antileukemia activity in an in vivo primary AML xenograft.

Slides:

Advertisements

Similar presentations

Inhibition of CR HCT-116 (A and B) or CR HT-29 cells (B) xenografts in EPA and/or FuOx-treated SCID mice. Inhibition of CR HCT-116 (A and B) or CR HT-29.

Advertisements

Mild preconditioning and low-level engraftment confer methotrexate resistance in mice transplanted with marrow expressing drug-resistant dihydrofolate.

Continuous in vivo infusion of interferon-gamma (IFN-γ) enhances engraftment of syngeneic wild-type cells in Fanca–/– and Fancg–/– mice by Yue Si, Samantha.

Morphological analyses of peripheral blood and bone marrow cells isolated from leukemic mice. Morphological analyses of peripheral blood and bone marrow.

AG-221 induces the differentiation of IDH2R140Q blasts along myeloid lineages in primary human AML xenograft models. AG-221 induces the differentiation.

AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia by Donya Moradi Manesh, Jad El-Hoss, Kathryn.

by Jonathan Hoggatt, Pratibha Singh, Janardhan Sampath, and Louis M

Effects of AG-221 treatment on survival and cell differentiation in an IDH2R140Q primary human AML xenograft model. Effects of AG-221 treatment on survival.

In vivo responses of AMLMLL to ATRi.

Fig. 8. In vivo suppression of MM by CMLD

Effects of SC144 on in vivo ovarian tumor.

The PI3K–Akt pathway is essential for the in vivo maintenance of murine Tregs. The PI3K–Akt pathway is essential for the in vivo maintenance of murine.

T Cell–Mediated Rejection of Human CD34+ Cells Is Prevented by Costimulatory Blockade in a Xenograft Model Annie L. Oh, Dolores Mahmud, Benedetta Nicolini,

Immunohistochemical analysis.

Fig. 7 BRD0705 impairs colony formation in AML cell lines and patient cells and shows in vivo efficacy in multiple AML mouse models. BRD0705 impairs colony.

VAY-736 combines effectively with ibrutinib in vivo.

Agonistic targeting of TLR1/TLR2 induces p38 MAPK-dependent apoptosis and NFκB-dependent differentiation of AML cells by Mia Eriksson, Pablo Peña-Martínez,

Inhibition of MEK and ATR is effective in a B-cell acute lymphoblastic leukemia model driven by Mll-Af4 and activated Ras by S. Haihua Chu, Evelyn J. Song,

Volume 30, Issue 5, Pages (November 2016)

CXCR5 expression accelerates Eμ-Tcl1 leukemogenesis and is indispensable for tumor cell recruitment to lymphoid B-cell follicles. CXCR5 expression accelerates.

Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in xenografted mice. Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in.

Fig. 5 ALRN-6924 shows robust antileukemic activity in primary AML cells and in vivo. ALRN-6924 shows robust antileukemic activity in primary AML cells.

MI-773 reduces the fraction of CSCs and prevents recurrence in ACC xenograft tumors. MI-773 reduces the fraction of CSCs and prevents recurrence in ACC.

Senescence-associated inflammation, bone marrow suppression, and cardiac dysfunction. Senescence-associated inflammation, bone marrow suppression, and.

ABT-199 efficiently kills primary AML myeloblasts as a single agent.

Engraftment of ROSAKIT D816V-Gluc cells in NSG mice.

Type I and III IFNR expression on hematopoietic cells is required for protection against IA. Type I and III IFNR expression on hematopoietic cells is required.

In vivo assessment of synergistic activity of MV-CEA and RT in a U87 s

Leukemic blasts express a “hypoxia signature

E-cadherin synthetic lethal effects operate in vivo in E-cadherin–defective breast tumors. E-cadherin synthetic lethal effects operate in vivo in E-cadherin–defective.

Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model in vivo. Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model.

GS87 demonstrates efficacy in a circulating AML mouse model system.

coTCRcys-transduced T cells control tumor growth in vivo.

EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. A,

Vascular staining in CWR22R xenograft tumors.

Antitumor activity of MLN8237 against TNBC patient-derived tumor xenografts (PDTX) in vivo. Antitumor activity of MLN8237 against TNBC patient-derived.

PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. A, 4T1/HAS3.

5FU-induced specific activation of CD8+ T cells.

Antitumor effects of celastrol in vitro and in vivo.

In vivo AraC treatment does not induce any consistent changes in CD34+/−CD38+/− phenotypes nor in quiescent leukemic cells but increases apoptotic cell.

MEDI4736 shows antitumor activity in xenograft mouse models of human cancer. MEDI4736 shows antitumor activity in xenograft mouse models of human cancer.

Combined loss of MPG and ATM sensitizes pGBM cells to temozolomide (TMZ) in vivo. Combined loss of MPG and ATM sensitizes pGBM cells to temozolomide (TMZ)

ESKM is superior to ESK1 in vivo, and is effective against multiple tumor models. ESKM is superior to ESK1 in vivo, and is effective against multiple tumor.

A protracted ketogenic diet increases radiation response in H292 lung cancer xenografts given conventional fractionated radiation. A protracted ketogenic.

ESKM treatment does not affect leukocyte or HSC counts in HLA-A

A, decreased vessel formation in basic fibroblast growth factor–supplemented Matrigel plugs excised from mice 10 days after treatment with the combination.

SY-1425 induces maturation in RARA-high AML

Systemic reovirus treatment targets disseminated human myeloma in vivo

A to C, MetMAb shows strong antitumor activity in the KP4 orthotopic model of pancreatic cancer by ultrasound. A to C, MetMAb shows strong antitumor activity.

Effect of CDV on human SF7796 xenografts in vivo.

YH25448 less suppresses WT EGFR than osimertinib in vivo.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

CDV potentiates the antitumor effect of ionizing radiation in mice intracerebrally implanted with human glioblastoma cells. CDV potentiates the antitumor.

MGA271 exhibits potent in vivo antitumor activity toward tumor cell carcinoma xenografts. MGA271 exhibits potent in vivo antitumor activity toward tumor.

TAE-684 effectively inhibits the growth of H3122 in vivo.

Effect of MZ treatment on lung colony formation in an experimental metastasis. Effect of MZ treatment on lung colony formation in an experimental metastasis.

Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy. Immune checkpoint molecule expression in primary and secondary.

Constitutive expression of JAK3M511I and HOXA9 leads to development of both AML and T-ALL in vivo. Constitutive expression of JAK3M511I and HOXA9 leads.

PDL192 and inhibit the growth of xenograft tumors.

Survival RR enhancement according to the specific protocol in treated mice. Survival RR enhancement according to the specific protocol in treated mice.

Flavopiridol inhibits rhabdoid cell survival and induces cell cycle arrest and apoptosis. Flavopiridol inhibits rhabdoid cell survival and induces cell.

Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC xenografts. Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC.

Inhibition of spontaneous pulmonary metastasis and prolonged survival after removal of primary tumor and intratracheal delivery of rAAV2/5-VAS. Inhibition.

Cabozantinib causes significant tumor cell elimination in vivo, but modest apoptosis induction in vitro. Cabozantinib causes significant tumor cell elimination.

Both TKI and EZH2i upregulate H3K27me3 targets, and combined treatment potentiates loss of LSCs. A, summary of global mean mRNA expression changes found.

Recruitment of CD8+, CD4+, and Foxp3+ cells into oral lesions in response to anti–PD-1 treatment. Recruitment of CD8+, CD4+, and Foxp3+ cells into oral.

BH3-targeted inhibitors drive specific resistance in human cell lines, which can be overcome with alternating or combining inhibitors. BH3-targeted inhibitors.

Curative effect of W+T treatment in vivo.

Inhibition of MCL1 reduces AML in an in vivo murine model.

Parthenolide inhibits tumor promotion and increases p21 expression in vivo. Parthenolide inhibits tumor promotion and increases p21 expression in vivo.

Presentation transcript:

TH-302 has antileukemia activity in an in vivo primary AML xenograft murine model. TH-302 has antileukemia activity in an in vivo primary AML xenograft murine model. TH-302 (50 mg/kg intraperitoneally three times a week for 3 weeks) reduced the number of circulating AML cells and prolonged survival of NSG mice engrafted with primary AML cells compared with the vehicle-treated mice. A, survival curves (N = 8/group) of vehicle-treated (control) and TH-302–treated mice. Line indicates onset and duration of treatment. B, total numbers of mononuclear cells (MN) or total human AML cells were determined in blood by FACS analysis after staining for huCD45 (N = 2 and 3 for control and TH-302–treated mice, respectively). C, PIMO immunostaining of bone marrow (BM) sections from control or TH-302–treated mice euthanized at the end of the treatment; 20 × magnification. D, survival curves of secondary transplant mice (N = 5/group). NSG mice were transplanted with 0.01 or 0.005 × 106 bone marrow cells isolated from primary recipients (A) treated with control or TH-302. Juliana Benito et al. Clin Cancer Res 2016;22:1687-1698 ©2016 by American Association for Cancer Research